The rise of Sildenafil initially drove a surge for pharma, however recent shifts present a murky outlook for investors. Generic versions are reducing profits, and persistent patent challenges add more risk to the https://adreavulh532484.suomiblog.com/viagra-and-the-pharmaceutical-industry-a-volatile-play-57007419